SANOFI-AVENTIS RECEIVES FDA APPROVAL FOR NEW ELOXATIN® FORMULATION

SANOFI-AVENTIS RECEIVES FDA APPROVAL FOR NEW ELOXATIN® FORMULATION Sanofi-aventis announced today that he has received marketing approval from the United States Food and Drug Administration for a new formulation of Eloxatin® (oxaliplatin for injection). This new formulation, Eloxatin® INJECTION, is a clear, preservative-free, colorless solution which does not require reconstitution. Eloxatin® INJECTION offers additional benefit and convenience to physicians and nurses since it involves fewer steps in the administration of Eloxatin®. For complete press release, se attached file! ------------------------------------------------------------ Ytterligere informasjon kan hentes på følgende hjemmeside: http://www.waymaker.no Nedenstående filer kan lastes ned: http://wpy.waymaker.net/client/waymaker1/WOLReleaseFile.aspx?id=68952&fn=wkr0001.pdf Press release, pdf